Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer
BJ Monk, TJ Herzog, SB Kaye, CN Krasner… - Journal of clinical …, 2010 - ascopubs.org
Purpose The objective of this study was to compare the efficacy and safety of trabectedin
plus pegylated liposomal doxorubicin (PLD) with that of PLD alone in women with recurrent …
plus pegylated liposomal doxorubicin (PLD) with that of PLD alone in women with recurrent …
Phase IB dose escalation and expansion study of AKT inhibitor afuresertib with carboplatin and paclitaxel in recurrent platinum-resistant ovarian cancer
SP Blagden, AL Hamilton, L Mileshkin, S Wong… - Clinical cancer …, 2019 - AACR
Purpose: Preclinically, AKT kinase inhibition restores drug sensitivity in platinum-resistant
tumors. Here the pan-AKT kinase inhibitor afuresertib was given in combination with …
tumors. Here the pan-AKT kinase inhibitor afuresertib was given in combination with …
[HTML][HTML] EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with …
Background In a phase III, randomised, active-controlled study (EMPOWER-Cervical 1/GOG-
3016/ENGOT-cx9; R2810-ONC-1676; NCT03257267) and cemiplimab significantly …
3016/ENGOT-cx9; R2810-ONC-1676; NCT03257267) and cemiplimab significantly …
ATL
TV Gorodnova, KB Kotiv, AO Ivantsov… - International Journal of …, 2018 - ijgc.bmj.com
Objectives Cisplatin and mitomycin C exert high activity towards BRCA1-deficient cells. This
study aimed to evaluate the efficacy of a combination of these drugs in hereditary BRCA1 …
study aimed to evaluate the efficacy of a combination of these drugs in hereditary BRCA1 …
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
JA Ledermann, R Shapira-Frommer, AD Santin… - Gynecologic …, 2023 - Elsevier
Objective This prespecified exploratory analysis evaluated the association of gene
expression signatures, tumor mutational burden (TMB), and multiplex immunohistochemistry …
expression signatures, tumor mutational burden (TMB), and multiplex immunohistochemistry …
Safety and efficacy of NEPA, an oral fixed combination of netupitant and palonosetron, in older patients
M Aapro, K Jordan, RJ Gralla, G Rizzi, G Rossi… - Journal of geriatric …, 2017 - Elsevier
Objectives Prevention of chemotherapy-induced nausea and vomiting is critical in older
patients with cancer. NEPA is an oral fixed combination of netupitant 300 mg, a new NK 1 …
patients with cancer. NEPA is an oral fixed combination of netupitant 300 mg, a new NK 1 …
Aromatase inhibitors of the third generation in endocrine therapy of breast cancer and endometrial cancer: the successes and failures of the combination therapy
EP Fadeeva, AS Lisyanskaya… - … and Drug Therapy, 2016 - journals.eco-vector.com
This review provides the current evidence of clinical studies on the effectiveness of
endocrine therapy for breast cancer and endometrial cancer, including endometrial stromal …
endocrine therapy for breast cancer and endometrial cancer, including endometrial stromal …
[CITATION][C] Place de la trabectédine plus doxorubicine liposomale pégylée dans le cancer de l'ovaire récidivant
BJ Monk, TJ Herzog, SB Kaye, CN Krasner… - J Clin Oncol, 2010